|
Real-time Estimate
Cboe Europe
17:32:56 12/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 134.20 CHF | +1.10% |
|
+0.15% | +22.55% |
| 11-11 | Novartis AG : Jefferies gives a Neutral rating | ZD |
| 11-11 | Amgen's Sjogren's drug cuts disease activity in trial | RE |
Company Valuation: Novartis AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 196,458 | 194,448 | 207,167 | 195,514 | 266,003 | 301,067 | - | - |
| Change | - | -1.02% | 6.54% | -5.62% | 36.05% | 13.18% | - | - |
| Enterprise Value (EV) 1 | 204,649 | 203,482 | 219,178 | 213,458 | 289,870 | 335,243 | 329,437 | 323,133 |
| Change | - | -0.57% | 7.71% | -2.61% | 35.8% | 15.65% | -1.73% | -1.91% |
| P/E | 8.2x | 28.3x | 14.1x | 16.5x | 19.2x | 23.9x | 18.8x | 16.7x |
| PBR | 2.9x | 3.23x | 4.41x | 4.52x | 5.73x | 6.65x | 6.15x | 5.66x |
| PEG | - | -0.4x | 0x | -1x | 0.9x | -3.15x | 0.7x | 1.3x |
| Capitalization / Revenue | 3.81x | 3.85x | 4.44x | 3.78x | 4.69x | 5.21x | 4.88x | 4.6x |
| EV / Revenue | 3.96x | 4.03x | 4.7x | 4.13x | 5.11x | 5.8x | 5.34x | 4.94x |
| EV / EBITDA | 11.2x | 10.9x | 12.2x | 10.2x | 12.4x | 14.1x | 12.9x | 11.8x |
| EV / EBIT | 12.3x | 12.2x | 13.4x | 10.9x | 13.2x | 15x | 13.7x | 12.5x |
| EV / FCF | 15.4x | 17x | 16.6x | 13.1x | 16.5x | 22.1x | 18.1x | 16.2x |
| FCF Yield | 6.49% | 5.87% | 6.01% | 7.61% | 6.07% | 4.53% | 5.54% | 6.17% |
| Dividend per Share 2 | 3.36 | 3.5 | 3.823 | 3.856 | 4.762 | 4.372 | 4.591 | 4.764 |
| Rate of return | 3.83% | 3.87% | 3.79% | 3.94% | 3.44% | 2.74% | 2.88% | 2.99% |
| EPS 2 | 10.71 | 3.19 | 7.15 | 5.92 | 7.21 | 6.663 | 8.483 | 9.57 |
| Distribution rate | 31.4% | 110% | 53.5% | 65.1% | 66% | 65.6% | 54.1% | 49.8% |
| Net sales 1 | 51,626 | 50,545 | 46,660 | 51,722 | 56,674 | 57,762 | 61,711 | 65,468 |
| EBITDA 1 | 18,246 | 18,613 | 17,937 | 21,006 | 23,415 | 23,722 | 25,603 | 27,367 |
| EBIT 1 | 16,588 | 16,665 | 16,372 | 19,494 | 21,889 | 22,363 | 24,019 | 25,844 |
| Net income 1 | 24,021 | 6,955 | 14,854 | 11,939 | 13,967 | 12,747 | 15,683 | 17,433 |
| Net Debt 1 | 8,191 | 9,034 | 12,011 | 17,944 | 23,867 | 34,175 | 28,370 | 22,065 |
| Reference price 2 | 87.82 | 90.40 | 100.79 | 97.79 | 138.63 | 159.41 | 159.41 | 159.41 |
| Nbr of stocks (in thousands) | 2,237,092 | 2,150,980 | 2,055,460 | 1,999,270 | 1,918,792 | 1,888,624 | - | - |
| Announcement Date | 02/02/22 | 01/02/23 | 31/01/24 | 31/01/25 | 04/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.92x | 5.8x | 14.13x | 2.74% | 301B | |
| 42.06x | 14.21x | 30.18x | 0.47% | 1,280B | |
| 41.04x | 6.89x | 19.37x | 1.9% | 675B | |
| 37.61x | 8.63x | 17.8x | 2.34% | 521B | |
| 21.6x | 5.24x | 13.13x | 2.49% | 386B | |
| 104.47x | 5.96x | 25.4x | 2.31% | 363B | |
| 24.1x | 4.84x | 13.6x | 1.8% | 286B | |
| 24.17x | 7.41x | 13.62x | 2.16% | 253B | |
| -39.88x | 7.38x | 46.48x | 1.95% | 211B | |
| 11.82x | 4.26x | 8.59x | 4.13% | 178B | |
| Average | 29.09x | 7.06x | 20.23x | 2.23% | 445B | |
| Weighted average by Cap. | 36.22x | 8.72x | 22.04x | 1.78% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- NOVN Stock
- Valuation Novartis AG
Select your edition
All financial news and data tailored to specific country editions
